The Form 4 filing was filed on Nov. 12, 2026, for sales made on Nov. 10. This SEC report of insider stock activity lists Martine A. Rothblatt as chairperson and CEO of United Therapeutics (UTHR).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-10 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 14 |
| Shares Transacted | 9,500 |
| Price | $586.32 |
| Total Transaction Value | $5,570,085.26 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were stock sales, shown by transaction code S. The reported activity covers 9,500 shares sold in 14 transactions, all dated Nov. 10, 2026.
What was the average price of the transaction?
The average sale price was $586.32 per share. The available transaction details give one average for the 14 sales, without listing a separate price for each sale.
How did this transaction affect the insider's holdings?
The sales reduced Martine A. Rothblatt's reported holdings by 9,500 shares, leaving 324,443 shares owned afterward. The shares sold made up 2.84% of the shares owned before the sales.
What's the total transaction value?
The total reported value was $5,570,085.26 across all 14 transactions. That amount covers the 9,500 shares sold.
Are there any special circumstances around this transaction?
The available filing information points to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. The footnote text is unavailable here, so it is unclear which of the 14 sales the plan covered. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.